Acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) are among the most severe forms of acute lung injuries with severe pulmonary edema and hypoxemia, which are seen in patients with sepsis, severe trauma, fat embolism and so on.
Tranilast (N-3,4-demethoxycinnamoyl-anthranilic acid) has been used clinically to treat allergic diseases, such as bronchial asthma, allergic rhinitis, atopic dermatitis, and hypertrophic scarring and keloid formation. Tranilast seems to have multiple anti-inflammatory effects, through inhibiting the production or releasing cytokines (e.g. tumor necrosis factor-a, interleukin-1b, and -8) or prostanoids (thromboxane A 2 and prostaglandin E 2 ) from monocytes 4) and superoxide 5) from PMNs. Nagai et al. 6) reported that tranilast ameliorated the pulmonary vascular hyper-permeability in lipopolysaccharide (LPS)-induced lung injury, one of the animal models of ARDS/ALI. Therefore, these anti-inflammatory effects of tranilast may work against ARDS/ALI caused by LPS. To extend the application of tranilast to the ARDS/ALI caused by factors other than LPS, it is necessary to examine the effects of tranilast on other animal models of acute lung injury.
The injection of oleic acid (OA), an endogenous unsaturated fatty acid, can produce lung injury with pulmonary vascular hyper-permeability and hypoxemia as well as ARDS/ALI. Since pathophysiological changes induced by OA are similar to those in patients with ARDS/ALI, OA-induced lung injury is known as one of the models of these diseases. 7) OA-induced lung injury resembles specific forms of ARDS/ALI that follow pancreatitis, 8) long bone fractures 9) and meconium aspiration, 10) all of which are thought to be caused by the toxicity of fatty acids. However, no research has been done to examine the effect of tranilast on lung injury induced by OA. The purpose of this study was to determine whether tranilast ameliorates pulmonary vascular hyper-permeability and hypoxemia induced by OA.
MATERIALS AND METHODS

Animals
Hartley strain guinea pigs (male, 650Ϯ85 g) were used. This study was approved by the Animal Care and Use Committee of Kumamoto University, and was performed in accordance with National Institutes of Health guidelines for the care and handling of animals. An operation was performed as described before.
11)
Animal Treatment Animals were divided randomly into the following groups: 1) tranilast (Kissei Pharmaceutical Co., Nagano, Japan), (100, 200 or 400 mg/kg)ϩOA (ICN Biomedicals Inc., Aurora, OH, U.S.A.) (15 ml/kg)-treated group (nϭ6), 2) 5% carboxymethyl cellulose (CMC) aqueous solution (2 ml/kg)ϩOA (15 ml/kg)-treated group (nϭ6) and, 3) 5% CMC (2 ml/kg)ϩsaline ( accomplished by inserting a 13-gauge blunt cannula through the right ventricle into the pulmonary artery, and perfusate outflow came out from the dissected left atrium. The lungs were perfused with 100 ml of saline at a rate of 3 ml/min using a pump (EYELAMicro Tube Pump MP-3, Rikakikai Co., Tokyo, Japan). After the perfusion, the airways and lungs were removed and weighed. The airways were separated into the trachea, main bronchus, and intrapulmonary bronchus. The intrapulmonary bronchus was further cut in two in the middle and divided into the proximal bronchus and the distal bronchus. After measurement of the wet weight, whole right lungs were cut into several sections (about 1 cm thick). Evans blue dye was extracted in 20 ml (for the pieces from the whole right lungs) and 2 ml (for the airways) of 100% formamide solution (Sigma) at 37°C for 18 h, and its concentration was determined by light absorbance at 620 nm with a spectrophotometer (U 3200, Hitachi Ltd., Tokyo, Japan). Interpolation of the data was performed using a standard curve for absorbance from 100 ng/ml to 5 mg/ml. The amounts of Evans blue dye extravasated from the tissues were then expressed as ng/mg of wet weight of tissue.
Measurement of Partial Oxygen Pressure of Arterial Blood
To examine the effect of tranilast on OA-induced hypoxemia, we measured the partial oxygen pressure of arterial blood (Pao 2 ). Animals were anesthetized, a catheter (1.1 mm outer diameter) was inserted into the subclavian artery for blood sampling, and the other catheter was inserted into the subclavian vein for the injection of OA. Tranilast (200 or 400 mg/kg) or 5% CMC was administered orally 2 h before the OA injection. Two hundred microliters of arterial blood was collected 5, 10 and 15 min before, and 6, 10, 15, 35, 55, and 75 min after the OA injection, and analyzed with a blood gas analyzer (ABL 300, RADIOMETER Ltd., Copenhagen, Denmark). The mean value of the Pao 2 before the OA injection was defined as the value at 0 min.
Statistical Analysis Results were expressed as meanϮ S.E. Multiple comparisons were made to examine the statistical significance of the data. When uniform variance of data was identified by Bartlett's analysis (pϽ0.05), one-way analysis of variance (ANOVA) was used to test for statistical differences. When significant differences (pϽ0.05) were identified, then the data were further analyzed by Dunnett's multiple range test for significant differences between the tranilast group and the OA control group. The data were analyzed using Student's unpaired t test to compare the OA control group with the saline control group.
RESULTS
Changes in Pulmonary Vascular
Permeability An injection of OA significantly increased the vascular permeability in the lungs and airways, as indicated by the extravasation of Evans blue given intravenously (Figs. 1, 2 ). In addition, distinctive patches of intense hemorrhage with Evans blue on the surface of the lungs were observed. Tranilast ameliorated the OA-induced increase in vascular permeability in the lungs and airways. Two hundred and 400 mg/kg tranilast significantly prevented vascular hyperpermeability in the whole right lungs (Fig. 1) , and 400 mg/kg tranilast significantly prevented that in the proximal and distal bronchus (Fig. 2) .
Changes in Pao 2 As shown in Fig. 3 , OA significantly decreased the Pao 2 . The maximum decrease in Pao 2 , approximately 45% of the value at 0 min, was observed 6 min after the OA injection. Seventy-five minutes after the OA injection, Pao 2 was recovered to approximately 90% of the value at 0 min. Tranilast significantly prevented the decrease in Pao 2 induced by OA, in a dose-dependent manner (Fig. 3) .
DISCUSSION
An intravenous injection of 15 ml/kg OA caused a significant immediate decrease in Pao 2 within 10 min after the injection. The decrease in Pao 2 was recovered to nearly nor- Tranilast, which was originally introduced as an anti-allergic drug, has recently attracted considerable attention because it has a variety of pharmacological actions, such as inhibition of the proliferation of fibroblasts and collagen deposition, 12) inhibition of cytokine release and production, 4, 13) inhibition of angiogenesis and vascular hyper-permeability induced by vascular endothelial growth factor, 14, 15) and so on. Based on these pharmacological potentials, tranilast has recently been used for the treatment of hypertrophic scars, keloids and restenosis after percutaneous transluminal coronary revascularization. In the meantime, it has been viewed as an attractive candidate for the treatment of some diseases which have no available drugs.
ARDS/ALI is severe acute lung injury with high mortality since there are no effective drugs for the prevention and/or treatment of the disease. In this study, to elucidate the potential of tranilast against ARDS/ALI, we examined the effect of the drug on OA-induced pulmonary and airway vascular hyper-permeability and hypoxemia, and proved for the first time that the administration of tranilast drastically ameliorated pulmonary and airway vascular hyper-permeability and hypoxemia induced by OA injection.
We reported that pentoxifylline, which has a potential to suppress neutrophils, inhibited OA-induced lung injury. 16) Furthermore, we showed that a release of superoxides from isolated polymorphonuclear leukocytes was induced within 30 min after an application of OA. We and also showed that both N-acetyl-cystein, which has a radical-scavenging effect, and MAAPVCK, which is an inhibitor of elastase, could significantly attenuate pulmonary vascular hyperpermeability 90 min after the OA injection. 17) These findings suggest that pulmonary hyperpermeability in OA-induced lung injury is concerned with neutrophil activation, and happens within 90 min after the OA injection.
In our other previous studies, we demonstrated that oxidative stress was an important mechanism of OA-induced lung injury, and that the reactive oxygen species may be produced through NADPH oxidase, a superoxide producing enzyme, and may be released from inflammatory cells such as PMNs. 17, 18) Tranilast can inhibit the superoxide production from activated PMNs, while the drug does not have a "scavenging effect". 5) Therefore, a probable explanation for the main mechanism of tranilast for the attenuation of the lung injury by OA seems to be the inhibition of superoxide production from inflammatory cells.
In addition, other inflammatory mediators such as proteases, 14) eicosanoids, 7) cytokines, 15) from PMNs and macrophages are likely to play an important part in the development of OA-induced pulmonary and airway vascular hyper-permeability, as well as ARDS/ALI. Tranilast seems to have favorable pharmacological effects against inflammatory reactions, because the drug is shown to inhibit the release and/or production of inflammatory mediators, such as histamine, eicosanoids and cytokines from PMNs 5) and monocytes. 4) These effects may be involved in the attenuation of pulmonary vascular hyper-permeability by OA.
Tranilast itself did not have any effects on Pao 2 and pulmonary permeability (data not shown). In terms of pulmonary vascular permeability, the effect of tranilast seems to have a ceiling effect, because there was not a significant difference between the effect of 200 mg/kg and that of 400 mg/kg. However, since there seems to be a dose dependence on the effect of tranilast on Pao 2 , tranilast may have some mechanism other than the prevention of hyperpermeability, such as the facilitation of HPV or pulmonary lympha flow. Further studies will be needed to prove the mechanisms of the inhibitory effect of tranilast.
Hypoxemia is a critical state which can result in brain damage and/or death, yet it is extremely difficult to improve the hypoxemia in patients with ARDS/ALI. Therefore, if tranilast has preventive effects against hypoxemia in the clinical area, it is intriguing as a candidate against ARDS/ALI. In this study, we proved that tranilast ameliorated the decrease in Pao 2 induced by OA. In our previous reports, we described that one of the main mechanisms of the decrease in Pao 2 in our system was an increase in pulmonary vascular permeability based on the effects of tranexamic acid, an inhibitor of plasmin, 11) and carbazochrome, a drug for the treatment of hemorrhage, 19) on OA-induced hypoxemia. Therefore, the preventive effect of tranilast on the decrease in Pao 2 by the OA injection, at least in part, may be through inhibition of the increase in pulmonary vascular permeability.
In our preliminary experiments, 20 and 50 mg/kg of tranilast did not show any effect on OA lung injury. Clinically, tranilast is administered at a dose of around 2 mg/kg. Therefore, the dose used in this experiment (100-400 mg/kg) is much higher compared with the clinical dose. However, "species difference" should be taken into consideration, so we cannot directly extrapolate the doses in animal experiments to clinical doses. In addition, in some animal experiments, 200-400 mg/kg doses were used. 5, 12) So the dose used in our experiment does not seem to be ridiculously high.
In addition, there is an interesting report about the effect of tranilast on a lung disease. Mori et al. 20) reported that tranilast suppressed bleomycin-induced fibrosing alveolitis in mice, an animal model of pulmonary fibrosis. In the case of ARDS/ALI, pulmonary fibrosis, which tends to be seen around 1 week after the initiation of ARDS, can lead to a severe reduction of lung compliance, and can be fatal.
3) It may be an attractive effect of tranilast against ARDS/ALI.
Considering these pharmacological properties, tranilast is a noteworthy drug that could be a candidate for the prevention and treatment of ARDS/ALI. We hope that the results of this study will lead to novel therapeutic strategies to prevent or ameliorate ARDS/ALI.
